Adaptimmune Therapeutics PLC (ADAPY) stock
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics statistics
42 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- –
- Last ex-dividend date
- No dividends
- Fundamentals through
- Jun 30, 2025
- Share price as of
- –
Share statisticsIndustry
- Shares Change (QoQ)
- 2.79%
- 0.48%
- Float
- 1.59B
- 49M
- Shares Held by Insiders
- 0.07%
- 12.1%
- Shares Held by Institutions
- 0.00%
- 56.4%
MarginsIndustry
- Pretax Margin
- -255.1%
- -11.8%
- EBITDA Margin
- -252.3%
- -27.7%
- FCF Margin
- -294.5%
- -8.85%
Returns on capitalIndustry
- Return on Assets (ROA)
- -129.9%
- -40.7%
- Return on Capital Employed (ROCE)
- -207.6%
- -38.1%
Financial positionIndustry
- Current Ratio
- 1.52
- 3.31
- Quick Ratio
- 0.69
- 2.41
- Interest Coverage
- -28.99
- -6.35
GrowthIndustry
- Revenue Growth (3Y CAGR)
- 207.1%
- 2.25%
- Revenue Growth (5Y CAGR)
- 175.5%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.50
- 0.40
- Revenue Per Employee
- $128.63K
- $429.38K
- Profits Per Employee
- -$335.49K
- -$683.67K
- Employee Count
- 506
- 75
Income statement (TTM)Industry
- Pretax Income
- -$166.05M
- -$13.23M
Balance sheetIndustry
- Net Cash (Debt)
- $386.00K
- $16.98M
- Net Cash Per Share
- $0.00
- $0.72
- Equity (Book Value)
- -$70.96M
- $52.68M
- Book Value Per Share
- -$0.04
- $1.50
- Tangible Book Value
- -$74.77M
- $26.74M
- Working Capital
- $26.60M
- $78.52M
Cash flow (TTM)Industry
- Capital Expenditures
- -$1.64M
- -$944.00K
- FCF Per Share
- -$0.12
- -$0.42
Taxes and interestIndustry
- Interest Expense
- $5.67M
- $2.97M
- Income Tax
- $3.71M
- $74.00K
Scores and fair valueIndustry
- Piotroski F-Score
- 3
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | ADAPY | S&P 500 | Difference | ADAPY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +55.6% | +0.6% | +54.9 pts | ||
| 3 months | -11.4% | +3.4% | −14.8 pts | ||
| Year to date | +34.6% | +13.3% | +21.3 pts | ||
| 1 year | -82.5% | +16.6% | −99.1 pts | ||
| 3 years | -94.0% | +86.4% | −180.3 pts | -60.8% | +23.1% |
| 5 years | -99.3% | +81.9% | −181.2 pts | -63.3% | +12.7% |
| 10 years | -99.3% | +318.9% | −418.2 pts | -39.4% | +15.4% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
1M ADAPY shares were sold short on Oct 30, 2026, up 0.0% from the previous report. At recent volumes it would take 3.1 days to buy them back.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 1,216,756 | +0.0% | 390,361 | 3.1 |
| Oct 15, 2026 | 1,216,755 | +0.0% | 244,300 | 5.0 |
| Sep 30, 2026 | 1,216,722 | -0.2% | 573,964 | 2.1 |
| Sep 15, 2026 | 1,218,986 | +0.0% | 262,835 | 4.6 |
| Aug 31, 2026 | 1,218,969 | +0.0% | 297,790 | 4.1 |
| Aug 14, 2026 | 1,218,960 | -0.0% | 219,584 | 5.5 |
| Jul 31, 2026 | 1,218,965 | +0.0% | 728,391 | 1.7 |
| Jul 15, 2026 | 1,218,960 | +0.0% | 1,134,451 | 1.1 |
| Jun 30, 2026 | 1,218,920 | +0.0% | 787,025 | 1.6 |
| Jun 15, 2026 | 1,218,904 | -45.4% | 2,029,656 | 1.0 |
| May 29, 2026 | 2,231,310 | +0.0% | 216,124 | 10.3 |
| May 15, 2026 | 2,231,307 | -0.7% | 862,082 | 2.6 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?